Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps

Peters, Anju T.; Han, Joseph K.; Hellings, Peter; Heffler, Enrico; Gevaert, Philippe; Bachert, Claus; Xu, Yu; Chuang, Chien‐Chia; Neupane, Binod; Msihid, Jérôme; Mannent, Leda; Guyot, Patricia; Kamat, Siddhesh

doi:10.1016/j.jaip.2021.01.031

Cited by 60 publications

(60 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The strengths of our systematic review and meta-analysis include a comprehensive and up-to-date search with broad eligibility and methodologic rigor in accordance with Cochrane and GRADE standards. Compared to previous meta-analyses including 4 to 9 RCTs on select biologics and comparisons, [11][12][13][14] our study contained 29 RCTs, uniquely informing comparative efficacy and safety across all biologics and ASA-D to maximally inform decision making.…”

Section: Discussionmentioning

confidence: 99%

“…One study reported a limited comparison between dupilumab and omalizumab. 14 None addressed comparative efficacy and safety across all biologics or in relation to ASA-D. We systematically reviewed and conducted network meta-analysis (NMA) of all available mAbs for CRSwNP. We integrated these findings from our prior systematic review and meta-analysis of ASA-D for CRSwNP to fully inform selection among competing treatments.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis

Oykhman

Paramo

Bousquet

et al. 2022

Journal of Allergy and Clinical Immunology

120

View full text Add to dashboard Cite

Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory condition of the upper airways. Optimal management is unclear. Objective: We compared the effects of mAbs and aspirin desensitization (ASA-D) for treatment of CRSwNP. Methods: We searched the Medline, Embase, Cochrane Central Register of Controlled Trials, International Clinical Trials Registry Platform, US Food and Drug Administration, and the European Medicines Agency databases from inception to August 4, 2021, for randomized controlled trials comparing the effects of mAbs and ASA-D for CRSwNP. We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events. We used the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach to assess certainty of evidence. PROSPERO CRD42020177334. Results: Twenty-nine randomized controlled trials evaluating 8 treatments (n 5 3461) were included in the network metaanalysis. Compared to placebo, moderate to high certainty evidence showed that health-related quality of life (SNOT-22) improved with dupilumab (mean difference [MD] 219.91 [95%

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis

Oykhman

Paramo

Bousquet

et al. 2022

Journal of Allergy and Clinical Immunology

120

View full text Add to dashboard Cite

show abstract

“…Although the direct comparison was not easy because of the methodological heterogeneity among the clinical trials, all biologics showed positive effects compared to the control treatment, with slight differences among themselves. Peters et al 48) reported that dupilumab had consistently greater improvements in outcomes versus omalizumab at week 24 in indirect treatment comparison of biologics in CRSwNP. Also, greater improvements in nasal polyp scores were observed after 52 weeks of dupilumab administration compared to that with omalizumab.…”

Section: Comparison Of Biologics In Crswnpmentioning

confidence: 99%

Practical Review of Biologics in Chronic Rhinosinusitis With Nasal Polyps

et al. 2021

View full text Add to dashboard Cite

Well-characterized in chronic rhinosinusitis, type 2 inflammation is frequently associated with nasal polyps, comorbid asthma, and nonsteroidal anti-inflammatory drug hypersensitivity. Despite medical and surgical treatment, it recurs in a significant proportion of patients. Thus, severe uncontrolled type 2 chronic rhinosinusitis with nasal polyps is the most difficult-to-treat phenotype of chronic rhinosinusitis. Recently, dupilumab, a monoclonal antibody against IL-4 receptor α, and omalizumab, a monoclonal antibody against immunoglobulin E, were approved for patients with chronic rhinosinusitis with nasal polyps in the United States, Europe, and Korea. Therefore, rhinologists should understand novel biologics and their use. Here, we provide a literature review of several biologics with their indications, effectiveness, and safety.

show abstract

“…Он применяется каждые 2-4 недели по схеме введения в дозах в зависимости от уровня IgE. Как показало недавно выполненное непрямое сравнение, омализумаб статистически значимо уступает дупилумабу в отношении снижения основных клинических проявлений ПРС в течение 24 недель применения [15] Оценка затрат на оказание медицинской помощи взрослым пациентам с ПРС и ТБА проводилась с учётом: прямых медицинских затрат (лекарственные и на оказание различных видов медицинской помощи), прямых немедицинских затрат (выплаты по временной и стойкой утрате трудоспособности, ВУТ и СУТ), непрямых затрат (потерь валового внутреннего продукта (ВВП)).…”

Section: фармакоэкономика качественная клиническая практика №3 2021 гunclassified

A social-economic burden of rhinosinusitis with nasal polyps with comorbid asthma and influence of dupilumab

Krysanov¹,

Krysanova

Ermakova³

2021

GCP

View full text Add to dashboard Cite

Rhinosinusitis with nasal polyps (RwNP) is a one of most common comorbidities in asthma and contrariwise and can lead to exacerbation of severe asthma (SA). Dupilumab is a perspective medicine for treatment of both, because it decreases exacerbations and prevents of a necessity of surgeon. Economics aspects of dupilumab treatment in RwNP + SA are not examined yet. Thus aim of this study was evaluation of social-economic burden of RwNP + SA in the Russian Federation and dupilumab influence on it. Materials and methods. Direct medical (cost of medicines, treatment in outpatients department and in hospital, including surgery and rate of exacerbations per year) and non-medical (payment for temporary and stable disability) and indirect costs (GDP loses) in RwNP + SA patients have been evaluated. Medical cure of a patient with RwNP + SA was created according to survey of experts from different regions of Russia. Modelling of expenditures was prepared on all calculated cohort of potential patients with RwNP + SA from “State” position and growing approach. Results. Expenditures for cure of one patient with RwNP were as 234 217,71 RUR/year. Weighted average costs for one patient with RwNP + SA were 1 881 883,39 RUR, and mostly were associated with indirect costs. Dupilumab can decrease expenditures for one patient with RwNP + SA till 1 593 162,87 RUR (on 15,3 %) annually. Potential cohort with RwNP + SA has been estimated above 39 thousand patients. Total economic burden of RwNP + SA in Russia were estimated as 1,7 bln RUR. Dupilumab usage in patients with RwNP + SA fixed in Register can help decrease economic burden on 259 mln RUR annually. Hidden economic burden of comorbidity can reach 73,4 bln RUR (for all calculated / modelled cohort of patients with RwNP + SA), dupilumab saves 11,3 bln RUR annually in this scenario. Conclusion. Comorbid pathology — RwNP+SA has a sufficient social-economic burden in Russia, that could be decreased by modern biologic drugs, in particular, with dupilumab.

show abstract

Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps

Cited by 60 publications

References 41 publications

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis

Practical Review of Biologics in Chronic Rhinosinusitis With Nasal Polyps

A social-economic burden of rhinosinusitis with nasal polyps with comorbid asthma and influence of dupilumab

Contact Info

Product

Resources

About